Europe Drug Prices Face Pressure as U.S. Benchmarking Tightens
Decision brief
Answer first · skim in under a minute
Europe drug prices are under fresh pressure as companies weigh how lower pricing in Europe could affect U.S. pricing power. The result may reshape launch sequencing, access strategy, and competitive positioning across major EU markets.
Europe drug prices are again a reference point for U.S. policy: CMS’s proposed GLOBE and related most-favored-nation-style models would tie certain Medicare rebates to international benchmarks drawn from economically comparable OECD countries, including large European markets.
Contents10 sections
Key Takeaways
- CMS proposed the GLOBE model to recalculate Medicare Part B inflation rebates using international price benchmarks.
- Proposed operation: five years from October 1, 2026 to September 30, 2031, covering about 25% of Medicare beneficiaries geographically.
- Nineteen OECD countries are listed as the comparator set for MFN-style benchmarking, including multiple European markets.
- European list prices and net prices are not identical; U.S. benchmarking pressure may change launch sequencing and EU negotiation tactics.
Why do U.S. models put pressure on Europe drug prices?
U.S. proposals that reference foreign prices make European list and net prices more strategically sensitive for global launch planning. If Medicare rebates rise when U.S. prices exceed an international benchmark, manufacturers may revisit EU launch timing, indication sequencing, and confidential rebate strategies.
CMS describes GLOBE on its model page at CMS: GLOBE (Global Benchmark for Efficient Drug Pricing).
What exactly does the proposed GLOBE model do?
GLOBE would test an alternative calculation for manufacturer rebates under the Medicare Part B Inflation Rebate Program using a benchmark derived from international pricing information instead of the current domestic benchmark alone.
According to the CMS press release proposing GLOBE, the model focuses on separately payable Part B drugs typically administered in clinical settings, such as cancer and autoimmune therapies.
- Mandatory model under CMS Innovation Center authority
- Rebates would continue to flow to the Medicare Supplementary Medical Insurance Trust Fund
- Biosimilars and their reference biologics would be excluded once a U.S. biosimilar enters the market, per CMS inclusion criteria summaries
Which European and peer markets sit in the comparator basket?
Policy explainers summarizing the GLOBE/GUARD proposals list 19 OECD countries for benchmarking, including Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, and the United Kingdom.
CMS would further filter to countries meeting purchasing-power-adjusted GDP thresholds (commonly described as at least 60% of U.S. GDP per capita and a minimum economy size of about $400 billion).
What should EU access and BD teams watch next?
Watch final rulemaking, geographic sampling for the 25% Medicare footprint, which Part B products are designated as GLOBE drugs, and how manufacturers report international prices. Parallel GUARD (Part D) and Medicaid GENEROUS concepts extend the same international-reference logic beyond physician-administered drugs.
For primary statutory and agency context, also track HHS communications on most-favored-nation prescription drug pricing at HHS.gov alongside CMS model pages.
What remains unproven?
Proposed models are not final law. Savings estimates, spillover effects on European net prices, and whether manufacturers raise EU prices, delay EU launches, or accept higher U.S. rebates are empirical questions that depend on final design and litigation outcomes.
Related NovaPharma coverage
- FDA Drug Approval: What Approval Means for Pharma Marketing and BD
- CHMP backs nerandomilast for IPF and PPF in EU
- FDA Approves First Interchangeable Biosimilars to Simponi
How might European launch and pricing tactics adapt?
If U.S. rebates rise when U.S. prices exceed an international basket that includes France, Germany, Italy, Spain and the United Kingdom, manufacturers may delay EU launches, narrow first indications in Europe, or protect net prices through confidential discounts that do not map cleanly into public list-price databases CMS might use.
Access teams in Europe should model two scenarios. First, U.S. policy finalises with manufacturer-reported international prices, increasing disclosure pressure on EU contracts. Second, litigation or redesign softens GLOBE, leaving Inflation Reduction Act inflation rebates as the dominant U.S. lever. Either path still increases the strategic value of European price governance because U.S. political attention remains fixed on cross-border differentials.
Hospital-administered Part B products are the first focus of GLOBE, so oncology and immunology franchises face earlier exposure than many retail Part D oral medicines covered under the parallel GUARD concept. Biosimilar entry can remove reference biologics from GLOBE inclusion under CMS criteria summaries, linking U.S. biosimilar strategy to international-benchmark risk.
For board-level planning, treat October 1, 2026 as a watch date rather than a certainty. Final geographic sampling, product lists, threshold percentages, and data sources will determine whether European list prices or confidential net prices become the binding constraint for global pricing committees.
Frequently Asked Questions
What is the CMS GLOBE model?
GLOBE is a proposed mandatory CMS Innovation Center model that would modify Medicare Part B inflation rebate calculations using international pricing benchmarks from economically comparable countries when U.S. prices exceed those benchmarks.
When would GLOBE run if finalized?
CMS has proposed a five-year GLOBE model beginning October 1, 2026 and ending September 30, 2031, applying to beneficiaries in defined geographic areas covering about 25% of Medicare beneficiaries.
Which countries are used for international benchmarking?
Proposed GLOBE/GUARD materials identify 19 OECD comparator countries, including major European markets such as France, Germany, Italy, Spain, the Netherlands, Sweden, Switzerland and the United Kingdom, subject to GDP per capita filters.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
